期刊
JOURNAL OF IMMUNOLOGY
卷 187, 期 1, 页码 92-101出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1100590
关键词
-
类别
资金
- Medical Research Council, U.K. [G0901755]
- Leukaemia and Lymphoma Research, U.K. [08012]
- MRC [G0901755] Funding Source: UKRI
- Medical Research Council [G9818340B, G0901755] Funding Source: researchfish
EBV, a B lymphotropic herpesvirus, encodes two immediate early (IE)-, > 30 early (E)-, and > 30 late (L)-phase proteins during its replication (lytic) cycle. Despite this, lytic Ag-induced CD8 responses are strongly skewed toward IE and a few E proteins only, all expressed before HLA I presentation is blocked in lytically infected cells. For comparison, we examined CD4(+) T cell responses to eight IE, E, or L proteins, screening 14 virus-immune donors to overlapping peptide pools in IFN-gamma ELISPOT assays, and established CD4(+) T cell clones against 12 defined epitopes for target-recognition assays. We found that the lytic Ag-specific CD4(+) T cell response differs radically from its CD8 counterpart in that it is widely distributed across IE, E, and L Ag targets, often with multiple reactivities detectable per donor and with IE, E, or L epitope responses being numerically dominant, and that all CD4(+) T cell clones, whether IE, E, or L epitope-specific, show strong recognition of EBV-transformed B cell lines, despite the lines containing only a small fraction of lytically infected cells. Efficient recognition occurs because lytic Ags are released into the culture and are acquired and processed by neighboring latently infected cells. These findings suggested that lytic Ag-specific CD4 responses are driven by a different route of Ag display than drives CD8 responses and that such CD4 effectors could be therapeutically useful against EBV-driven lymphoproliferative disease lesions, which contain similarly small fractions of EBV-transformed cells entering the lytic cycle. The Journal of Immunology, 2011, 187: 92-101.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据